WARREN, N.J., March 02, 2021 (GLOBE NEWSWIRE) — Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference, being held virtually March 9-10, 2021.
The presentation will be available on-demand beginning on Tuesday, March 9, 2021, in the Investors section on the Company’s website at www.bellerophon.com.
About Bellerophon
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary and infectious diseases. The Company is currently developing multiple product candidates under its INOpulse® program, a proprietary pulsatile nitric oxide delivery system. For more information, please visit www.bellerophon.com.
Contacts
| At W2O Group: | At LifeSci Advisors: |
| Julie Normart | Brian Ritchie |
| (559) 974-3245 | (212) 915-2578 |
| jnormart@w2ogroup.com | britchie@lifesciadvisors.com |
Dublin, Ireland--(Newsfile Corp. - April 12, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43)…
Both the Mast Hill $3,500,000 Note and the FirstFire $277,777 Note were Paid in Full…
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading…
SPARKS, MD / ACCESSWIRE / April 11, 2024 / TridentCare is excited to announce the…
LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health Companies Inc. (NYSE:NHC)(TSX:BHC) will…
STOCKHOLM, SWEDEN / ACCESSWIRE / April 11, 2024 / PMD Device Solutions (FRA:8T0)(STO:PMDS) ("PMDS") today…